Article info
PDFCommentary
AI diagnoses terminal illness care limits: just, or just stingy?
- Correspondence to Professor Leonard Michael Fleck, Center for Ethics, Michigan State University, East Lansing, Michigan, USA; fleck{at}msu.edu
Citation
AI diagnoses terminal illness care limits: just, or just stingy?
Publication history
- Received May 21, 2024
- Accepted August 18, 2024
- First published August 29, 2024.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design
- Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
- Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts’ interviews
- What is CAR T-cell therapy?
- SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report
- Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
- Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy
- Threats by artificial intelligence to human health and human existence
- Implications of conscious AI in primary healthcare
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2